Human microbiome market to reach $4.85b by 2031

APAC is expected to grow the fastest in the coming years.

The global human microbiome market is projected to grow from $1.07b in 2023 to $4.85b by 2031, with a CAGR of 20.8%, according to a report by Insights Partner.

The microbiome, comprising microorganisms such as bacteria and viruses that live throughout the human body, plays a crucial role in health and disease management.

Companies are heavily investing in research to develop advanced probiotics, diagnostics, and treatments. Kanvas Biosciences raised $12m in June 2023 to advance microbiome mapping technology. Nestlé and APC Microbiome Ireland formed a partnership in July 2023 to create new health-focused products. Over 120 companies are active in the sector, with major investors including Flagship Pioneering, Seventure Partners, and BioGaia.

Governments are also accelerating microbiome research through grants and regulatory support. The National Institutes of Health (NIH) has allocated $115m over five years for the Human Microbiome Project, aimed at advancing the understanding of human health and disease prevention.

Regulatory developments are also shaping the market landscape. In April 2023, the FDA approved Seres Therapeutics' VOWST, the first oral microbiome therapy to prevent recurrent Clostridioides difficile infection in adults. Europe is similarly advancing with reclassification measures, as Spain, Germany, and Switzerland now categorize vaginal probiotics as drugs, offering clearer regulatory pathways for market entry.

The Asia-Pacific region is expected to grow the fastest in the coming years.